Anifrolumab (systemic lupus erythematosus (SLE))

Subject:

• Active Substance: Anifrolumab
• Name: Saphnelo^®
• Therapeutic area: Systemic lupus erythematosus (SLE)
• Pharmaceutical company: AstraZeneca GmbH
   

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 06.10.2022
   

Final decision:

• No additional benefit proved